Reviva Pharmaceuticals (RVPH)
(Real Time Quote from BATS)
$2.15 USD
-0.67 (-23.76%)
Updated May 9, 2024 01:30 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RVPH 2.15 -0.67(-23.76%)
Will RVPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RVPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for RVPH
12 Health Care Stocks Moving In Thursday's Intraday Session
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
Reviva Pharmaceuticals’ Financial Turmoil: The High Cost of Restating Finances and its Impact on Stability
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023